- Home
- SPRY vs MDXG Comparison
SPRY vs MDXG Comparison
Compare SPRY & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPRY | MDXG |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | 200 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 558.9M | 625.6M |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SPRY | MDXG |
|---|---|---|
| Price | $5.62 | $4.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $40.00 | $9.00 |
| AVG Volume (30 Days) | ★ 1.5M | 926.8K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | $84,278,000.00 | ★ $418,630,000.00 |
| Revenue This Year | $87.40 | N/A |
| Revenue Next Year | $81.64 | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $4.91 | $3.03 |
| 52 Week High | $13.15 | $7.97 |
Technical Indicators
Market Signals| Indicator | SPRY | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 53.85 |
| Support Level | $5.04 | $4.11 |
| Resistance Level | $6.58 | $4.48 |
| Average True Range (ATR) | 0.37 | 0.17 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 35.14 | 39.32 |
Price Performance
Historical ComparisonAbout SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.